Detroit Receiving Hospital

About: Detroit Receiving Hospital is a healthcare organization based out in Detroit, Michigan, United States. It is known for research contribution in the topics: Vancomycin & Population. The organization has 877 authors who have published 850 publications receiving 37202 citations. The organization is also known as: Detroit General.

The impact of a multidisciplinary educational intervention to reduce PEG tube placement in patients with terminal-stage dementia: A translation of research into practice

Abstract: The purpose of this translation of research into practice (TRIP) project was to to determine the impact of a multidisciplinary education-consultation intervention to reduce percutaneous endoscopic gastrostomy (PEG) tube placement in patients with terminal-stage dementia at a single urban hospital in a city characterized by numerous health care transitions. We attempted a “just-in-time” approach to educate busy clinicians through explicit recommendations offered during routine and requested consultation. The project results showed that the intervention had a modest positive clinical impact.

Evaluation of Bacteriophage Cocktails Alone and in Combination with Daptomycin Against Daptomycin-Nonsusceptible Enterococcus faecium

Abstract: Enterococcus faecium(E. fcm) is a significant multidrug-resistant pathogen. Bacteriophage cocktails are being proposed to complement antibiotic therapy. After a screen of 8 E. fcm strains against 4 phages, two phages(113, 9184) with the broadest host ranges were chosen for further experiments. Transmission electron microscopy, whole-genome sequencing, comparative genome analyses, and time-kill analyses were performed. Daptomycin(DAP) plus phage cocktail(113:myophage;9184:siphopage) showed bactericidal activity in most regimens, while DAP addition prevented phage 9184 resistance against daptomycin non-susceptible E. fcm.

Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function.

Abstract: Study Objective. Our institution developed dosing guidelines for patients with renal impairment based on pharmacokinetic data and class-specific pharmacodynamics. Ceftizoxime was chosen as a model agent to evaluate if the modified guidelines achieved similar minimal plasma concentration (Cpmin) and time above the minimum inhibitory concentration of the infecting organism (T>MIC) in patients with renal impairment versus those with normal renal function. Design. Prospective pharmacokinetic and pharmacodynamic evaluation of ceftizoxime dosages. Setting. University-affiliated hospital. Patients. Forty-three patients with suspected or documented infection were enrolled and classified into four groups based on creatinine clearance (Clcr; ml/min): group 1, above 100; group 2, 61–99; group 3, 31–60; and group 4, 15–30. Interventions. Ceftizoxime serum concentrations were obtained at steady state. Measurements and Main Results. Pharmacokinetic and pharmacodynamic parameters were calculated. As expected, clearance and elimination rate constant were reduced, and half-life tended to be greater in patients with renal impairment. The Cpmin and area under the concentration-time curve over 24 hours were similar between groups (p=0.39, p=0.42). The T>MIC was 100% for all patient isolates, and 90% or more versus our clinical strain for all groups. Clinical outcomes were similar among all groups. Conclusion. Our dosing guidelines achieved similar Cpmin among all groups of patients. Our results support that recommendations for dosing adjustments should be based on pharmacokinetic data and must also consider pharmacodynamic parameters.